Refactor Capital

About

Refactor Capital is a seed-stage venture capital firm based in Burlingame, California, founded in 2016 ¹. The firm was co-founded by David Lee, formerly managing partner at SV Angel, and Zal Bilimoria, formerly a partner at Andreessen Horowitz, along with Rick Barber, a former data scientist at a16z ²³. The firm’s debut fund (Fund I) closed at $50 million in 2016 ². In 2019, David Lee stepped back from active investing to become Chairman, and Rick Barber departed, making Bilimoria the sole general partner ³⁴. Lee stated at the time that becoming Chairman would allow him to “spend more time in Los Angeles, work more closely with current Refactor portfolio founders and pursue new adventures” ⁴.

Since transitioning to a solo GP structure, Bilimoria has raised three additional funds: Fund II at $36 million (closed May 2019) ⁴⁵, Fund III at $50 million ⁵, and Fund IV at $50 million (closed June 2024, with deployment beginning July 2024) ⁶⁷. Fund IV closed in under 90 days, with approximately 90% of capital from existing investors ⁶⁷. Across all funds and SPVs, Refactor manages approximately $225 million in assets ⁸⁹.

Refactor operates as a solo capitalist firm by design. Bilimoria is the sole decision-maker, and the firm has no other investment professionals ¹⁸. The firm typically writes lead or co-lead checks of $1–2 million into pre-seed and seed rounds, targeting approximately 10% ownership ¹¹⁰. Each fund targets a portfolio of 20–25 companies deployed over three years ⁷⁹. Since its 2016 launch, Refactor has invested in over 100 companies, of which four have become unicorns ⁶⁷.

Refactor provides portfolio founders with complimentary mental health therapy through a Lyra Health partnership, covering not only founders but also their employees ⁸⁹. The firm also offers advisor access for financial and HR guidance and support with fundraising, financial strategy, and storytelling ¹⁸.

Stated Thesis

Refactor publicly describes its mission as backing founders who are “refactoring the real world” — applying the computer science concept of refactoring (making code more efficient without changing its function) to physical-world industries ¹⁷. The firm states it invests in hard tech companies across aerospace, energy, biology, earth systems, and physical AI ¹.

Bilimoria has stated that the firm is built around “a simple belief: the most enduring companies are created by founders willing to commercialize real science” ⁸. He has described the investment focus as addressing “fundamental human problems” that “typically reside within traditionally regulated industries” ¹¹.

The firm publicly states it avoids med-tech devices, single-asset therapeutics, traditional enterprise software, and consumer mobile apps ¹.

Inferred Thesis

Based on 55 verified portfolio companies from the firm’s website ¹², Refactor’s actual investment behavior shows the following patterns:

Sector distribution (55 verified companies): - Biotech/life sciences: 16 of 55 (29%) — includes drug discovery, genomics, cell therapy, and therapeutics (64x Bio, Gencove, Loyal, Octant Bio, YourChoice Therapeutics, Parallel Bio, Adventris, Granza Bio, Vitra Bio, Phytoform, Epana Bio, Miist Therapeutics, Pilgrim Labs, BioRender, Orchid, TBC) - Health/wellness: 10 of 55 (18%) — includes digital health, healthtech, and wellness (PathAI, Headspace, Picnic Health, Lucy, Ophelia Health, Vital Health, Akasa, Curative, Atlas, Able) - Critical materials/chemicals: 6 of 55 (11%) — manufacturing biology-derived chemicals and materials (Checkerspot, Macro Oceans, Aether, Solugen, Berkeley Yeast, Knowde) - Energy: 5 of 55 (9%) — battery, nuclear, data center, and powertrain technologies (Lumindt, Network Ocean, Pila Energy, Hexium, Brelle) - Earth systems/climate: 4 of 55 (7%) — weather, flood insurance, land restoration, emissions (Causal Labs, Floodbase, Remedy Scientific, Thalo Labs) - Aerospace: 2 of 55 (4%) — satellite and spacecraft companies (Astranis, General Galactic) - Other/stealth: 12 of 55 (22%) — includes 6+ stealth companies and a few categorization-edge companies

Stage distribution: The firm invests almost exclusively at the seed stage, with some pre-seed participation. Graduate companies include several that received follow-on investment from Refactor through subsequent rounds (e.g., Solugen through Series D) ⁴.

Geographic focus: Primarily US-based companies, consistent with the firm’s stated focus ¹.

Notable patterns: - Biology is the dominant thread, appearing across biotech, health, critical materials, and earth systems categories. Combined, biology-adjacent companies represent roughly 58% of the verified portfolio (32 of 55). - The portfolio shows a strong tilt toward companies with deep IP or science-based moats — university spinouts, novel platform technologies, and companies commercializing academic research. - Despite claiming to avoid enterprise software, the portfolio includes several software-heavy companies (BioRender, Knowde, Akasa, Vital Health), though these tend to serve scientific or healthcare verticals rather than general enterprise. - The energy sector allocation has grown in recent funds, reflecting a stated expansion into climate tech.

Co-investor patterns: Based on verified co-investment data, frequent co-investors include Y Combinator, Social Capital, Fifty Years, BoxGroup, and Kindred Ventures ⁴¹³¹⁴.

Exits: The portfolio has produced 3 IPOs (Coinbase/$COIN, Clover Health/$CLOV, and one other) and multiple acquisitions, including PathAI (acquired by Quest Diagnostics, 2024), Betty Labs/Locker Room (acquired by Spotify, 2021), and Able (acquired by Health Catalyst) ¹²¹⁵¹⁶.

Note: This analysis is based on 55 companies visible on the firm’s portfolio page, representing roughly half of the 100+ total claimed investments. The full portfolio may show different distributions.

Portfolio

Note: Years marked with “~” are estimates based on company founding dates or fund deployment timelines, not confirmed investment dates. Most entries without independent round confirmation are labeled “Seed” consistent with the firm’s stated strategy of leading seed rounds. This table represents approximately half of Refactor’s 100+ total investments. Coinbase and Headspace investment rounds could not be independently confirmed and may have been made through SPVs or secondary transactions.

In Their Own Words

“Being a solo capitalist allows me to move fast, build trust quickly…Investment decisions happen in days, not weeks or months.” — Zal Bilimoria, Refactor Capital Fund IV press release, June 2024 ⁷

“The term ‘refactor’ means making code more efficient, applied here to startups transforming industries.” — Zal Bilimoria, Refactor Capital Fund IV press release, June 2024 ⁷

“We are only in the graces of this wonderful profession because of them.” — Zal Bilimoria, on founders, 20VC podcast ¹¹

“Being a solo GP gives me the ability to make lightning fast decisions — often producing term sheets in 3 weeks or less.” — Zal Bilimoria, Pulse2 interview ⁹

“I pick up the tab for mental health services, not only for founders but their employees as well.” — Zal Bilimoria, Pulse2 interview ⁹

“You have to be able to believe that every single investment you make can return the fund.” — Zal Bilimoria, 20VC podcast ¹¹

“These fundamental human problems are those that typically reside within traditionally regulated industries.” — Zal Bilimoria, 20VC podcast ¹¹

“We haven’t seen many dedicated seed funds in these areas, especially those like us, who want to be that largest check in the seed round.” — Zal Bilimoria, 20VC podcast ¹¹

“I know the types of founders I want to invest in. I want to spend a lot of time with them. I want to create a concentrated portfolio of 20 to 25 companies every fund.” — Zal Bilimoria, Alejandro Cremades interview ²⁰

“Are they technically and commercially gifted? Are they going to be magnets for three types of people, customers, talent, and investors?” — Zal Bilimoria, on founder evaluation, Alejandro Cremades interview ²⁰

What Founders Say

No independently sourced founder testimonials found. Refactor Capital’s website does not feature public founder testimonials, and dedicated searches across Twitter/X, press coverage, and podcast transcripts did not surface verifiable founder quotes about their experience with the firm.

Sources